explore -WSS

explore

author：leisure time 2025-09-27 19:37:30 - browse：3

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： An interview with Robert F. Kennedy Jr. on vaccines

WSS

AstraZeneca bets AAV gene therapy will still deliver the goods

How a symptom of dementia informs our understanding of creativity

Lung cancer is America's deadliest cancer. Yet so few get screened

NYU Langone launches private ChatGPT for its health care data

Medicare explains how it will choose drugs for negotiation

Winners, losers from Medicare’s list of drugs subject to price talks

leisure time

explore

explore

Wildfire smoke exposes gaps in outdoor worker protections

Complete sequence of Y chromosome published for first time

Walensky prepares to leave CDC — and Congress — behind

Lung cancer is America's deadliest cancer. Yet so few get screened

Duchenne breakthrough therapy leaves behind pioneering families

FDA approves first treatment for ultra

Continuity nursing helped my family in our darkest PICU moments

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Continuity nursing helped my family in our darkest PICU moments

Medicare explains how it will choose drugs for negotiation

explore

Australia’s approach to dialysis celebrates life

Evacuations in place as 3 wildfires burn in eastern Washington state

FDA approves first treatment for ultra

Patient advocates sound warning on FDA proposal on salt intake

New definition of a human embryo proposed amid rapid advances

The pain doctors face in trying to build their families

explore

Wikipedia

Wikipedia

focus